Company intelligence / Profile preview
Sentynl Therapeutics, Inc.
Solana Beach, California, United Statessentynl.com ↗
- Ownership
- Private
- Employees
- ~27000
- Development stage
- Commercial
01
Overview
The company has published clinical studies showing statistically significant prolonged survival in MoCD Type A patients treated with NULIBRY (fosdenopterin) compared to untreated patients. They also have CUTX-101 (copper histidinate) under FDA priority review for Menkes disease with a PDUFA date of June 30, 2025[4][6][9].
- Therapeutic areas
- Rare Diseases
- Modalities
- Small moleculesbiologics
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Fortress Biotech, Inc. (FBIO)Cyprium Therapeutics
Beyond the preview
Go deeper on Sentynl Therapeutics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sentynl Therapeutics, Inc..